Ni species, dose and lung effects
|
Male
|
Female
|
Male
|
Female
|
Nickel subsulphide:
| | | | |
Dose in % of MTDa, b
|
(0, 15, 100)
|
(0, 15, 100)
|
(0, 50, 100)
|
(0, 50, 100)
|
Chronic active inflammation rate
|
(9/53, 53/53, 51/53)
|
(7/53, 51/53, 51/53)
|
(1/61, 52/59, 53/58)
|
(1/58, 46/59, 58/60)
|
Macrophage hyperplasia rate
|
(9/53, 48/53, 52/53)
|
(8/53, 51/53, 52/53)
|
(6/61, 57/59, 58/58)
|
(5/58, 57/59, 60/60)
|
Alveolar/bronchiolar adenoma or carcinoma rate
|
(0/53, 6/53, 11/53)
|
(2/53, 6/53, 9/53)f
|
None
|
None
|
Nickel oxide:
| | | | |
Dose in % of MTDc
|
(0, 25, 50, 100)
|
(0, 25, 50, 100)
|
(0, 25, 50, 100)
|
(0, 25, 50, 100)
|
Chronic inflammation rate
|
(28/54, 53/53, 53/53, 52/52)
|
(18/53, 52/53, 53/53, 54/54)
|
(0/57, 21/67, 34/66, 55/69)
|
(7/64, 43/66, 53/63, 52/64)
|
Alveolar/bronchiolar adenoma or carcinoma rate
|
(1/54, 1/53, 6/53, 4/52)f
|
(1/53, 0/53, 6/53, 5/54)
|
None
|
(6/64, 15/66, 12/63, 8/64)
|
Nickel sulphate hexahydrate:
| | | | |
Dose in % of MTDd
|
(0, 25, 50, 100)
|
(0, 25, 50, 100)
|
(0, 25, 50, 100)
|
(0, 25, 50, 100)
|
Chronic active inflammation rate
|
(14/54, 11/53, 42/53, 46/53)
|
(14/52, 13/53, 49/53, 52/54)
|
(1/61, 2/61, 8/62, 29/61)
|
(1/61, 7/60, 14/60, 40/60)
|
Macrophage hyperplasia rate
|
(7/54, 9/53, 35/53, 48/53)
|
(9/52, 10/53, 32/53, 45/54)
|
(6/61, 9/61, 35/62, 59/61)
|
(7/61, 24/60, 53/60, 59/60)
|
Neoplastic effects
|
None
|
None
|
None
|
None
|
|
Wistar rats
| | |
Nickel metal:
| | | | |
Dose in % of MTDe
|
(0, 25, 100)
|
(0, 25, 100)
| | |
Chronic inflammation rate
|
(14/50, 44/50, 41/50)
|
(16/50, 45/50, 45/54)
| | |
Neoplastic effects
|
Noneg
|
Noneg
| | |